NAN-101 in Patients With Class III Heart Failure

Summary

Participation Requirements

Description

The primary endpoint for this study is safety as measured by the following which will be assessed over the 12 month follow-up period as indicated in the Data Collection Table: Adverse Events All-cause Mortality Heart failure (HF) Hospitalization Secondary Endpoints The secondary safety endpoints ass...

The primary endpoint for this study is safety as measured by the following which will be assessed over the 12 month follow-up period as indicated in the Data Collection Table: Adverse Events All-cause Mortality Heart failure (HF) Hospitalization Secondary Endpoints The secondary safety endpoints assessed will include the following: Echocardiographic assessments at 4 weeks +/- 3 days post-administration of BNP116.sc-CMV.I1c including Echocardiographic assessments of LVEF, LVEVD, LVEDVI, VLESV, LVEVI, SpI and GLSand degree of mitral regurgitation o The secondary efficacy endpoints will explore efficacy. Functional endpoints will be assessed as changes from baseline to 6 and 12 months following investigational product administration as indicated. These endpoints include: Functional Status & Hospitalizations Peak VO2 assessed by cardiopulmonary exercise testing 6-minute walk test New York Heart Association (NYHA) Classification Total number of days alive out-of-hospital (as well as total days out-of-hospital as a % of total days alive post study intervention) Physiologic Assessments at 6 and 12 months compared to baseline Echocardiographic assessments of LVEF, LVEVD, LVEDVI, VLESV, LVEVI, SpI and GLSand degree of mitral regurgitation NT-proBNP level Quality of Life at 6 and 12 months compared to baseline o Health related quality of life as assessed by Minnesota Living with Heart Failure Questionnaire (MLWHFQ) The following endpoints will also be measured over the 12 month follow-up period and long-term follow-up period (until month 36 post-intervention): Survival Cardiac transplantation Left ventricular assist device (LVAD) implantation

Tracking Information